The trials will test the ability of the firm's fluorine-18 labeled PET tracer to detect FAP-expressing tumor cells in ...
The grant will support a Phase I study of an anti-CD64 CAR T-cell therapy in patients with acute myeloid leukemia.
The partners want to develop personalized therapeutics and diagnostics based on insights derived from the Middle Eastern biorepository.
The firm said at the JP Morgan Healthcare Conference that it wants zorevunersen to be approved as a disease-modifying ...
Merck Still Wants to "Grow Through Keytruda," Expects $70B in Revenue From New Programs by Mid-2030s
At the JP Morgan Healthcare Conference, the firm highlighted two antibody-drug conjugates among 10 programs that will fuel ...
The firm said at the JP Morgan Healthcare Conference that a pivotal Phase III study, testing daraxonrasib in RAS-mutant ...
Genethon has licensed to AskBio a component of a preclinical gene therapy approach for treating Pompe disease.
Researchers will use a quantitative continuous scoring platform to measure patients' tumors for TROP2 expression in the trial.
The firm at the JP Morgan Healthcare Conference additionally expects a regulatory decision on its gene therapy RGX-121 for Hunter syndrome next month.
The company in 2026 is seeking approval from global regulators for Casgevy and two cystic fibrosis drugs in younger patients.
The company is also anticipating new data on its antibody-drug conjugate Trodelvy in PD-L1-high non-small cell lung cancer ...
The firm hopes to become a commercial-stage company this year, if the KIT inhibitor bezuclastinib is approved by the FDA as expected.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback